Resources

Aravax announced the appointment of Dr Adrian Parry as Director of CMC (Chemistry, Manufacturing and Controls), based at the Company’s Oxford, UK site.

A Scottish clinical development company is redefining early stage development, taking years off the time it takes for new life improving treatments to become available to patients. BDD Pharma Ltd – based at BioCity Glasgow, one of two Pioneer Group sites in Scotland – has also developed its own, in-house technologies. One of them - OralogiK™ - is a unique patented drug delivery tablet system that enables drugs to be released inside the body at the optimum time, hours after taking the tablets.

Moderna Innovation and Technology Centre (MITC) at Harwell Science and Innovation Campus has been granted a Manufacturer’s/Importer’s Authorisation (MIA) by the MHRA.

Proprietary formulation technology is being applied to potentially enhance properties of nimacimab.

BIA publishes its 10-year Vision for the UK life science sector, the culmination of 18 months of research and engagement with members and the broader life science ecosystem.

BIA is pleased to announce the appointment of Lucy Foley, Chief Technology Officer at eXmoor Pharma, as Vice Chair of its Manufacturing Advisory Committee (MAC).

Expanding Apprenticeship Pathways - Supporting RNA Medicines, oligos, Quality, Digital and Automation and Manufacturing through ATAC.

Plans for a major development on land at one of Europe’s largest R&D sites have been given the go-ahead.

Oligos explainer: A new frontier in precision medicine, highlights the transformative potential of oligonucleotide therapies. These precision medicines, which use short DNA or RNA molecules to target specific genes, offer groundbreaking solutions for diseases previously deemed untreatable, from rare genetic disorders to cancer.

Innovate UK has announced an investment over £14 million across 29 innovative projects to help make the UK’s medicines manufacturing sector more sustainable.

Brainomix has announced a strategic partnership with Medtronic Neurovascular, a global leader in medical technology.

Axplora unveils a €50 million investment at its Mourenx site, strengthening its role in producing next-generation therapies, including GLP-1 drugs for diabetes and obesity.

Touchlight’s dbDNA technology is the first synthetic DNA technology to receive a GMP certificate globally.

hVIVO plc announces that it has successfully completed a pilot characterisation study for its human metapneumovirus (hMPV) strain A2 challenge agent, demonstrating proof-of-concept for a future hVIVO hMPV challenge model to test new vaccines and antivirals.

Plexāā, a London-based medical device startup, is thrilled to announce a new partnership with Panasonic Manufacturing UK as their contract manufacturer for the award-winning BLOOM⁴³ medical device.

Stablepharma and AJ Vaccines have established the primary commercial distribution deal with proposed terms, in relation to the distribution and commercialisation of the SPVX02 (Td) in Europe.